Vincristine in high-grade glioma

Anticancer Research

Volumn 30, Issue 6, 2010, Pages 2303-2310

  Aydin, Burca ^a,b   Patil, Monali ^c   Bekele, Nebiyou ^b   Wolff, Johannes E A ^b  

^a ANKARA ONCOLOGY HOSPITAL   (Turkey)

^b UNIVERSITY OF TEXAS   (United States)

^c UNIVERSITY OF TEXAS SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

HGG; High grade glioma; Outcome; Treatment; Vincristine

Indexed keywords

CARMUSTINE; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DACARBAZINE; ETOPOSIDE; HYDROXYUREA; LOMUSTINE; NIMUSTINE; PROCARBAZINE; TEMOZOLOMIDE; VINCRISTINE;

ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; CLINICAL TRIAL; COHORT ANALYSIS; DISEASE SEVERITY; DRUG ANTAGONISM; DRUG EFFECT; DRUG EFFICACY; DRUG POTENTIATION; GLIOBLASTOMA; GLIOMA; HIGH GRADE GLIOMA; HUMAN; META ANALYSIS; OLIGODENDROGLIOMA; OVERALL SURVIVAL; PRIORITY JOURNAL; SYSTEMATIC REVIEW;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRAIN NEOPLASMS; CHILD; CHILD, PRESCHOOL; FEMALE; GLIOMA; HUMANS; INFANT; INFANT, NEWBORN; MALE; MIDDLE AGED; VINCRISTINE;

EID: 77955071987     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Stupp R, Mason WP, van den Bent MJ, Weiler W, Fisher B, Taphoorn MJB, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E and Mirimanoff RO: Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352(10): 987-996, 2005.
2. Huncharek M, Kupelnick B and Bishop D: Platinum analogues in the treatment of recurrent high grade astrocytoma. Cancer Treat Rev 24(5): 307-316, 1998. (Pubitemid 28537767)
3. Goerne R, Bogdahn U and Hau P: Procarbazine - a traditional drag in the treatment of malignant gliomas. Curr Med Chem 15(14): 1376-1387, 2008.
4. Wolff JE, Berrak S, Koontz Webb SE and Zhang M: Nitrosourea efficacy in high-grade glioma: a survival gain analysis summarizing 504 cohorts with 24193 patients. J Neurooncol 88(1): 57-63, 2008.
5. Stupp R, Dietrich PY, Ostermann Kraljevic S, Pica A, Maillard I, Maeder P, Meuli R, Janzer R, Pizzolato G, Miralbell R, Porchet F, Regli L, de Tribolet N, Mirimanoff RO and Leyvraz S: Promising survival for patients with newly diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide. J Clin Oncol 20(5): 1375-1382, 2002.
6. Wick A, Pascher C, Wick W, Jauch T, Weller M, Bogdahn U and Hau P: Rechallenge with temozolomide in patients with recurrent gliomas. J Neurol 256(5): 734-741, 2009.
7. Jeremic B, Shibamoto Y, Gruijicic D, Milicic B, Stojanovic M, Nikolic N, Dagovic A and Aleksandrovic J: Combined treatment modality for anaplastic oligodendroglioma: a phase II study. J Neurooncol 43(2): 179-85, 1999.
8. Bertolone SJ, Yates AJ, Boyett JM, Wallace D, Finlay JL; Children's Cancer Group: Combined modality therapy for poorly differentiated gliomas of the posterior fossa in children: a Children's Cancer Group report. J Neurooncol 63(1): 49-54, 2003. (Pubitemid 36681642)
9. Levin VA, Hess KR, Choucair A, Flynn PJ, Jaeckle KA, Kyritsis AP, Yung WK, Prados MD, Bruner JM, Ictech S, Gleason MJ and Kim HW: Phase III randomized study of postradiotherapy chemotherapy with combination alpha- difluoromethylornithine-PCV versus PCV for anaplastic gliomas. Clin Cancer Res 9(3): 981-990, 2003.
10. Geyer JR, Sposto R, Jennings M, Boyett JM, Axtell RA, Breiger D, Broxson E, Donahue B, Finlay JL, Goldwein JW, Heier LA, Johnson D, Mazewski C, Miller DC, Packer R, Puccetti D, Radcliffe J, Tao ML, Shiminski-Maher T; Children's Cancer Group: Multiagent chemotherapy and deferred radiotherapy in infants with malignant brain tumors: a report from the Children's Cancer Group. J Clin Oncol 23(30): 7621-7631, 2005.
11. Cairncross G, Berkey B, Shaw E, Jenkins R, Scheithauer B, Brachman D, Buckner J, Fink K, Souhami L, Laperierre N, Mehta M and Curran W: Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma: Intergroup Radiation Therapy Oncology Group Trial 9402. J Clin Oncol 24(18): 2707-2714, 2006.
12. Levin VA, Silver P, Hannigan J, Wara WM, Gutin PH, Davis RL and Wilson CB: Superiority of post-radiotherapy adjuvant chemotherapy with CCNU, procarbazine, and vincristine (PCV) over BCNU for anaplastic gliomas: NCOG 6G61 final report. Int J Radiat Oncol Biol Phys 18(2): 321-324, 1990. (Pubitemid 20097526)
13. Hauch H, Sajedi M and Wolff JE: Treatment arms summarizing analysis of 220 high-grade glioma studies. Anticancer Res 25(5): 3585-3590, 2005. (Pubitemid 41105245)
14. Levin VA, Wara WM, Davis RL, Vestnys P, Resser KJ, Yatsko K, Nutik S, Gutin PH and Wilson CB: Phase III comparison of BCNU and the combination of procarbazine, CCNU, and vincristine administered after radiotherapy with hydroxyurea for malignant gliomas. J Neurosurg 63(2): 218-223, 1985.
15. Burton EC and Prados MD: Malignant gliomas. Curr Treat Options Oncol 1(5): 459-468, 2000.
16. Rappelle AC, Postma TJ, Taphoorn MJ, Groeneveld GJ, van den Bent MJ, van Groeningen CJ, Zonnenberg BA, Sneeuw KC and Heimans JJ: PCV chemotherapy for recurrent glioblastoma multiforme. Neurology 56(1): 118-120, 2001.
17. Murphy C, Pickles T, Knowling M and Thiesse B: Concurrent modified PCV chemotherapy and radiotherapy in newly diagnosed grade IV astrocytoma. J Neurooncol 57(3): 215-220, 2002.
18. Ron IG, Gal O, Vishne TH and Kovner F: Long-term follow-up in managing anaplastic astrocytoma by multimodality approach with surgery followed by postoperative radiotherapy and PCV-chemotherapy: phase II trial. Am J Clin Oncol 25(3): 296-302, 2002.
19. Jackson DV Jr., Sethi VS, Spurr CL, Willard V, White DR, Richards F 2nd, Stuart JJ, Muss HB, Cooper MR, Homesley HD, Jobson VW and Castle MC: Intravenous vincristine infusion: phase I trial. Cancer 48(12): 2559-2564, 1981. (Pubitemid 12194242)
20. Kellie SJ, Koopmans P, Earl J, Nath C, Roebuck D, Uges DR and De Graaf SS: Increasing the dosage of vincristine: a clinical and pharmacokinetic study of continuous-infusion vincristine in children with central nervous system tumors. Cancer 100(12): 2637-2643, 2004.
21. Stewart DJ: A critique of the role of the blood-brain barrier in the chemotherapy of human brain tumors. J Neurooncol 20(2): 121-139, 1994.
22. Chastagner P, Kalifa C, Doz F, Bouffet E, Gentet JC, Ruchoux MM, Bracard S, Desandes E and Frappaz D: Outcome of children treated with preradiation chemotherapy for a high-grade glioma: results of a French Society of Pediatric Oncology (SFOP) Pilot Study. Pediatr Blood Cancer 49(6): 803-807, 2007.
23. Brandes AA, Turazzi S, Basso U, Pasetto LM, Guglielmi B, Volpin L, Iuzzolino P, Amistà P, Pinna G, Scienza R and Ermani M: A multidrug combination designed for reversing resistance to BCNU in glioblastoma multiforme. Neurology 58(12): 1759-1764, 2002.
24. Finlay JL, Boyett JM, Yates AJ, Wisoff JH, Milstein JM, Geyer JR, Bertolone SJ, McGuire P, Cherlow JM, Tefft M, Turski PA, Wara WM, Edwards M, Sutton LN, Berger MS, Epstein F, Ayers G, Allen JC and Packer RJ: Randomized phase III trial in childhood high-grade astrocytoma comparing vincristine, lomustine, and prednisone with the eight-drags-in-1-day regimen. Children's Cancer Group. J Clin Oncol 13(1): 112-123, 1995.
25. Buie LW and Valgus J: Bevacizumab: a treatment option for recurrent glioblastoma multiforme. Ann Pharmacother 42(10): 1486-1490, 2008.